Clinical Trial Search

Primary: 1-year Overall Survival (OS) — 80 percentage of participants

Primary: Mean Change From Baseline in Hemoglobin (Hgb) on Day 29 — 9.91; 0.63 Grams per decilitre (g/dL) — p=0.0020

Primary: Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average — 10.43; 10.55; 10.52; 0.00 Grams per deciliter (g/dL)

Primary: Overall Response Rate (ORR) — 3.226 percentage of participants

Primary: Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6) — 9.46; 9.93; 9.86; 9.67 Grams per deciliter (g/dL) — p=<0.0001

Primary: Treatment 1-6 and Unintentional Dosing Arms: Percentage of Participants With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Greater Than 5.27…

Primary: Percentage of Participants Achieving a Successful Hemoglobin Response — 54.9; 10.3 Percentage of participants — p==0.0001

Primary: Percentage of Treatment Responders at Months 12 and 24 — 64.1; 50.0; 67.5; 58.5 percentage of participants

Primary: Response Rate (RR) — 4.8; 0 percentage of participants

Primary: Change in Knee Pain — -0.93; -0.72; -0.93; -0.71 score on a scale — p=0.004

Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 16 — -0.02; -0.49; -0.91; -1.03 Percent — p=0.0071

Primary: Changes in Combined Positive Scoring (CPS) in Non-irradiated Sites Assessed by Flow Cytometry — 3.9 fold change — p=0.60

Primary: Clinical Benefit Rate (CBR) — 15.4 percentage of participants

Primary: Number of NTZ Treated Participants Presenting Any Treatment Emergent Adverse Event (TEAE) — 20; 7; 10; 3 Participants

Primary: Difference in Estimated (PEEP Adjusted) P/F Ratio at 7 Days — 281.4; 260.9 ratio